Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 12 №3 2010 год - Нефрология и диализ

Применение ритуксимаба при идиопатическом гломерулонефрите и системных заболеваниях с поражением почек (обзор литературы)


Захарова Е.В.

Аннотация: В данном обзоре мы представляем данные международной литературы, касающиеся обоснования, дозирования и результатов применения анти-CD20 моноклональных антител (Ритуксимаба) при хроническом гломерулонефрите с нефротическим синдромом, системной красной волчанке, АНЦА-ассоциированных васкулитах и HCV-ассоциированном криоглобулинемическом васкулите.

Весь текст



Ключевые слова: ритуксимаб, иммуносупрессивная терапия, гломерулонефрит, системная красная волчанка, системные васкулиты, rituximab, immunosuppressive therapy, glomerulonephritis, systemic lupus erythematosus, systemic vasculitis

Список литературы:
  1. Ahmed M.S., Wong C.F. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? // J Nephrol, 2007. Vol. 20. P. 350-356
  2. Ahmed M.S., Wong C.F. Rituximab and nephritic syndrome: a new therapeutic hope? // NDT, 2008. Vol. 23. P. 11-17
  3. Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome // N Engl J Med, 2007. Vol. 356. P. 2751-2752
  4. Benz K., Dotsch J., Rascher W. et al. Change of course of steroid-dependent nephrotic syndrome after rituximab therapy // Pediatr Nephrol, 2004. Vol. 19. P. 794-797
  5. Bosch X. Rituximab in ANCA vasculitis: bittersweet results // Nature reviews, 2010. Vol. 6. P. 137-139
  6. Cacoub P., Delluc A., Saadon D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? // Ann Rheum Dis, 2008. Vol. 67. P. 283-287
  7. E.D. Charles, L.D. Dustin. Hepatitis C virus-induced cryoglobulinemia // Kidney Int, 2009. Vol. 76. P. 818-824
  8. Cobo M., Hernandez D., Rodriguez C. et al. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis // Clin Nephrol, 2006. Vol. 66. P. 54-57
  9. Favas C., Isenberg D.A. B-cell depletion therapy in SLE – what are current prospects for its acceptance? // Nat Rev Rheumatol, 2009. Vol. 5. P. 711-2009
  10. Ferrario A.J., Smith S.W., Neil D. et al. Relapsed Wegener’s granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent “depletion” of peripheral blood // NDT, 2008. Vol. 23. P. 3030-3032
  11. Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment in idiopathic membranous nephropathy // Kidney Int, 2008. Vol. 73. P. 117-125
  12. Francois H., Daugas E., Bensman A. et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in adult; first case report and pathophysiological considerations // Am J kidney Dis, 2007. Vol. 49. P. 158-161
  13. Furie R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results of randomized, double-blind phase III LUNAR study // Arthritis Rheum, 2009 [online]
  14. Furie R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial // Arthritis Rheum, 2009 [online]
  15. Gilbert R.D., Hulse E., Rigden S. Rituximab therapy for steroid-dependent minimal change nephritic syndrome // Pediatr Nephrol, 2006. Vol. 21. P. 1698-1700
  16. Hofstra J.M., Deegens J.K., Wetzels J.F. Rituximab: effective treatment for severe steroid-dependent minimal-change nephrotic syndrome? // NDT, 2007. Vol. 22. P. 2100-2102
  17. Lovric S., Erdbruegger U., Kumpers P. et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center experience with 15 patients // NDT, 2009. Vol. 24. P. 179-185
  18. Merrill J.T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]
  19. Merrill J.T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78 week safety data from phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]
  20. Nellessen C.M., Poge U., Brensing K.A. et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus patient successfully treated with rituximab: a case report // NDT, 2008. Vol. 23. P. 385-386
  21. Remuzzi G., Chiurchiu C., Abbate V. et al. Rituximab for idiopathic membranous nephropathy // Lancet, 2002. Vol. 360. P. 923-924
  22. Rossi P., Demoux A.L., Granel B. et al. Anti-CD20 monoclonal antibody or treatment of refractory autoimmune haemolytic anemia associated with idiopathic membranous nephropathy // Rheumatology (Oxford), 2005. Vol. 44. P. 403-405
  23. Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study // Am J Soc Nephrol, 2003. Vol. 14. P. 1851-1857
  24. Saadoun D., Rosenzwaig M., Landau D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis // Blood, 2008. Vol. 111. P. 5334-5341
  25. Saadoun D., Rigon M.R., Sene D. et al. Rituximab Plus Peg-Interferon-alpha/Ribaverin Compared with Peg-Interferon-alpha/Ribaverin in Hepatitis C-Related Mixed Cryoglobulinemia // Blood, 2010. Vol. 116. P 326-354
  26. Sansonno D., De RE V., Lauetta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with anti-CD20 // Blood, 2003. Vol. 101. P. 3818-3826
  27. Sanz I., Lee F.E. B Cells as Therapeutic Targets in SLE // Nat Rev Rheumatol, 2010. Vol. 6. P. 326-337
  28. Sfikakis P.P., Boletis J.N., Lionaki S. et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial // Arthritis Rheum, 2005. Vol. 52. P. 501-513
  29. Smith G.C. Is there a role of rituximab in the treatment of idiopathic childhood nephrotic syndrome? // Pediatr nephrol, 2007. Vol. 22. P. 893-898
  30. Stone J.H. et al. Rituximab versus cyclophosphamide for induction remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) // Arthritis Rheum, 2009 [online]
  31. Vigna-Perez M., Hemandez-Castro B., Paredes-Saharopulos O. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study // Arthritis Res Ther, 2006. Vol. 8: R83
  32. M. Walsh, D. Jayne. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future // Kidney Int, 2007. Vol. 72. P. 676—682
  33. Yang T., Nast C.C., Vo A. et al. Rapid remission of steroid and mycofenolate mofetil (mmf)-resistant minimal change nephritic syndrome after rituximab therapy // NDT, 2008. Vol. 23. P. 377-380

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"